Bayer AGXSWX:BAYN 54 Buyback Yield % is 0.00 as of Jun. 27, 2026. GuruFocus rates XSWX:BAYN with a GF Score™ of 54/100 and a GF Value™ of CHF24.74 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 291 Drug Manufacturers companies, Bayer AG ranks worse than 343642.27% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Bayer AG's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BAYN vs LLY, JNJ, ABBV: Buyback Yield % Comparison
For the Drug Manufacturers - General subindustry, Bayer AG's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bayer AG Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bayer AG's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Bayer AG's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bayer AG (XSWX:BAYN) has a Buyback Yield % of 0.00 as of Jun. 27, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Bayer AG and its competitors. According to the industry distribution chart, Bayer AG ranks #999999 out of 291 companies in the Drug Manufacturers industry.
Is Bayer AG's Buyback Yield % too high?
Bayer AG's current Buyback Yield % is 0.00. Based on the distribution chart, Bayer AG ranks #999999 out of 291 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bayer AG has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's Buyback Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Bayer AG ranks #999999 out of 291 companies for Buyback Yield %. This places Bayer AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Bayer AG and its competitors. Bayer AG's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.74, compared to a current price of CHF42.49 — trading 71.7% above its estimated fair value. The current Buyback Yield % is 0.00. Bayer AG's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current Buyback Yield % is 0.00 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bayer AG (XSWX:BAYN) Overvalued in 2026?
Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued.
The current stock price of CHF42.49 is trading 71.7% above its estimated GF Value™ of CHF24.74.
GuruFocus considers Bayer AG to be Significantly Overvalued.
Key valuation signals for XSWX:BAYN:
Buyback Yield %: 0.00
GF Value™: CHF24.74 vs. price of CHF42.49 (71.7% above fair value)
No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
54GF Score
Get the complete analysis for XSWX:BAYN
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BAYN has been successfully added to your 
